Advocacy organization Public Citizen has sued the U.S. Food and Drug Administration (FDA), seeking a court order requiring the agency to issue a decision on its 2011 petition urging FDA to require black box warnings about certain purported adverse events associated with the use of proton pump inhibitors (PPIs), prescribed for the suppression of stomach acid. Public Citizen v. FDA, No. 14-0751 (U.S. Dist. Ct., D.D.C., filed April 30, 2014). According to Public Citizen, FDA’s delay in ruling on its petition constitutes a violation of the Administrative Procedure Act. Claiming that PPIs “are one of the most widely used classes of drugs in the United States, with 131 million prescriptions dispensed in 2013,” Public Citizen alleges that “FDA’s failure to require adequate warnings on PPI labeling counsels in favor of expeditious action on Public Citizen’s petition,” because of evidence showing that the drugs “pose serious safety risks about which their labeling does not warn.”